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Abstract
Background: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been
established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer
patients, monotherapy with SUN was associated with good tolerability but limited tumor response.
Methods: This double-blind, placebo-controlled, multicenter, phase II clinical trial was conducted to evaluate the
efficacy, safety and tolerability of SUN as an adjunct to second and third-line FOLFIRI (NCT01020630). Patients were
randomized to receive 6-week cycles including FOLFIRI plus sodium folinate (Na-FOLFIRI) once every two weeks
and SUN or placebo (PL) continuously for four weeks followed by a 2-week rest period. The primary study endpoint
was progression-free survival (PFS). Preplanned serum analyses of VEGF-A, VEGF-D, VEGFR2 and SDF-1α were
performed retrospectively.
Results: Overall, 91 patients were randomized, 45 in each group (one patient withdrew). The main grade ≥3 AEs
were neutropenia and leucopenia, observed in 56 %/20 % and 27 %/16 % for FOLFIRI + SUN/FOLFIRI + PL,
respectively. Median PFS was similar, 3.5 vs. 3.3 months (hazard ratio (HR) 1.11, 95 % CI 0.70–1.74, P = 0.66) for
FOLFIRI + SUN vs. FOLFIRI + PL, respectively. For FOLFIRI + SUN, a trend towards longer median overall survival (OS)
compared with placebo was observed (10.4 vs. 8.9 months, HR 0.82, 95 % CI 0.50–1.34, one-sided P = 0.21). In
subgroup serum analyses, significant changes in VEGF-A (P = 0.017), VEGFR2 (P = 0.012) and VEGF-D (P < 0.001)
serum levels were observed.
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Conclusions: Although sunitinib combined with FOLFIRI did not improve PFS and response in chemotherapy-
resistant gastric cancer, a trend towards better OS was observed. Further biomarker-driven studies with other
anti-angiogenic RTK inhibitors are warranted.
Trial registration: This study was registered prospectively in the NCT Clinical Trials Registry (ClinicalTrials.gov) under
NCT01020630 on November 23, 2009 after approval by the leading ethics committee of the Medical Association of
Rhineland-Palatinate, Mainz, in coordination with the participating ethics committees (see Additional file 2) on
September 16, 2009.
Keywords: Chemorefractory advanced gastric cancer, Tyrosine kinase inhibitor, Sunitinib, FOLFIRI, VEGF
Abbreviations: AIO, Arbeitsgemeinschaft Internistische Onkologie
Background
Overall survival (OS) for patients with locally advanced
and metastatic gastric cancer (AGC) remains poor with
a median OS of 8–11 months [1–3]. Many clinical trials
have investigated novel first-line chemotherapeutic com-
binations without demonstrating a clear survival benefit
compared with standard regimens [1, 4, 5]. Several pro-
spective randomized trials indicate a significant increase
in OS for second-line chemotherapy compared with best
supportive care (BSC) [6, 7]. Although none of the in-
vestigated combination regimens demonstrated signifi-
cant advantages over the others, the combination of
irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOL-
FIRI) is accepted as a safe and efficient chemotherapeu-
tic treatment for patients with refractory AGC [2].
Tumor angiogenesis, growth and metastasis can be
inhibited by blocking receptor tyrosine kinases (RTKs)
which are known to be overexpressed in human gastric
cancer (GC), including vascular endothelial growth factor
receptors (VEGFRs) or platelet-derived growth factor re-
ceptors (PDGFRs) [3, 8]. Furthermore, disease progression
or poor survival is associated with VEGF-A, epithelial
growth factor receptor (EGFR) and PDGF-A expression in
the tumor [9, 10]. Serum VEGF levels are significantly
higher in GC patients with remaining tumor and decrease
with radical resection. High preoperative serum VEGF-A
correlate with poor survival, tumor invasion and distant
metastases [11]. In contrast, in GC patients treated with
the VEGF-A antibody bevacizumab high plasma VEGF-A
predicted improved OS [12, 13]. Interestingly, the prognos-
tic significance of VEGF-A concentrations could be demon-
strated for non-Asian population only [12, 14]. Additionally,
a correlation of VEGF expression in GC tumor tissue with
histopathological response was shown [11, 13, 15, 16].
Agents such as gefitinib, erlotinib and cetuximab spe-
cifically target RTKs through a dominant receptor path-
way and have been investigated in phase II-III studies in
patients with AGC [17]. However, in many tumors, sev-
eral RTKs are co-expressed [8]. In addition, the initiation
of alternative angiogenesis signaling pathways under
therapy with anti-angiogenic agents represents a poten-
tial cause for therapy resistance of tumor cells [18–20].
Stromal cell-derived factor-1 (SDF-1α), also known as
CXCL12, may induce proliferation, dissemination and
immune evasion of several tumor tissues with several
existing variants [18, 19, 21–23]. However, studies inves-
tigating its expression in GC specimens have revealed
inconsistencies regarding its occurrence in cancer tissue
and its correlation with clinical characteristics [24, 25].
Sunitinib malate (SUN) is an oral, multi-targeted RTK
inhibitor of VEGFR-1, −2 and −3, PDGFR-α and -β and
several other RTKs [26, 27] and may have additional
benefits compared to single receptor targeted inhibition.
In two recent phase II studies in patients with chemore-
fractory AGC, SUN showed promising activity and man-
ageable toxicity [28, 29]. Therefore, this phase II clinical
trial was conducted to evaluate the efficacy, safety and
tolerability of SUN versus placebo (PL) as add-on ther-
apy to the second-line FOLFIRI treatment regimen.
Methods
Study design and treatment
This randomized, double-blind, placebo-controlled, mul-
ticenter, phase II study was conducted at 15 sites in
Germany after approval of the leading and the local eth-
ics committees. It was performed according to the Inter-
national Conference on Harmonisation – Good Clinical
Practice and the Declaration of Helsinki and was registered
in the public NCT Clinical Trials Registry (ClinicalTrials.
gov) under NCT01020630.
After signing informed consent, patients (SUN-CASE
inclusion/exclusion criteria: Additional file 1: Table S1)
were randomized to receive either SUN or PL in
addition to the two-weekly FOLFIRI plus sodium folinate
(Na-FOLFIRI) chemotherapy backbone. Patients were
treated until occurrence of any of the following: progres-
sive disease, intolerable adverse events (AEs), any AE that
resulted in treatment interruption of >14 days within the
active treatment cycle or >4 weeks between consecutive
active treatment cycles, or withdrawal of consent.
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SUN (starting dose: 25 mg) or PL was administered
orally once daily for four consecutive weeks followed by
a 2-week rest period. The dose of SUN could be in-
creased to 37.5 mg at the discretion of the treating phys-
ician and upon approval by the Data and Safety
Monitoring Board (DSMB) in patients tolerating 25 mg
in the first cycle without dose-limiting toxicities. The
dose could be reduced to 12.5 mg in patients experien-
cing SUN-related toxicity.
FOLFIRI was administered as the following regimen:
Irinotecan (180 mg/m2) was given intravenously on day
1, immediately followed by 5-FU bolus (400 mg/m2) and
46-h infusion of sodium folinate (400 mg/m2) and 5-FU
(2000 mg/m2) every two weeks, i.e. three courses of
FOLFIRI in every 6-week SUN/PL cycle [30]. Treatment
continued until disease progression or occurrence of un-
acceptable toxicity/AEs.
Biomarker analysis
An important inclusion criterion was the existance of at
least one blood sample before first medication intake
(baseline) and a further available sample during the
study. The peripheral blood samples were collected at all
15 participating study centers. After collection, specimens
were centrifuged to separate the serum which was stored
at −80 °C. Serum samples were tested in duplicate for con-
centrations of VEGF-A, VEGF-D, soluble VEGFR2 and
SDF-1α on days 1 + 14 of the first cycle. Furthermore, pre-
medication serum samples from day 1 of cycle 2 and cycle
3 were evaluated. The following enzyme-linked immuno-
sorbent assays (Duo-ELISA - R&D, Minneapolis) were
performed for quantification of serum levels using stand-
ard curves for concentration calculation: Duoset® ELISA
Human VEGF (DY293B), Duoset® ELISA Human VEGF-
D/FIGF (DY622), Duoset® ELISA Human VEGFR2/KDR
(DY357) and Duoset® ELISA Human CXCL12/SDF1
(DY350) according to manufacturer’s protocols.
Safety and efficacy assessment
AEs were graded according to the National Cancer Insti-
tute (NCI) Common Terminology Criteria for AEs
(CTCAE), version 4.0.
Tumor response was measured by computed tomog-
raphy scan after cycle 1 and 2, then after every 2 cycles,
assessed and graded by RECIST 1.1. Screening assess-
ments were carried out within 28 days prior to the start
of treatment. After the end of treatment (EOT), an EOT
visit was performed within 30 days. Patients were
followed-up every 3 months for 1 year thereafter.
Trial objectives and statistical analysis
The primary endpoint was progression-free survival
(PFS) according to RECIST 1.1. Secondary endpoints
were objective response rate, tumor control rate
(complete response [CR] + partial response [PR] + stable
disease [SD]), duration of disease stabilization, 1-year
OS, and the safety and tolerability of the placebo-
controlled combination therapy compared to the stand-
ard second-line therapy.
In total, 90 patients were to be enrolled to assign 43
patients to each treatment arm, taking into account a
drop-out rate of 5 %. A median PFS of 3 months was as-
sumed for the control group. A total of 86 events had to
be observed to show a 50 % improvement (4.5 months
median PFS) under SUN versus PL to ensure a power of
80 %, at a one sided significance level α of 15 %.
All statistical analyses were performed using SPSS®
Statistics. Measured biomarker values were partially log-
transformed for statistical purposes. Kaplan-Meier ana-
lysis with log-rank test was performed to estimate PFS
and OS. Cox proportional hazards model was used for
survival and covariates analyses. Proportions of adverse
events were compared by chi-square test or Fisher’s
exact test if the event occurred in less than 10 patients.
Non-parametric Wilcoxon-tests were used to compare
serum levels between different samples. To assess corre-
lations between serum levels and clinical parameters,
Spearman coefficients, non-parametric Mann–Whitney
and Jonckheere-Terpstra tests were performed. Tests
with P < 0.05 were considered statistically significant.
The primary analysis population was the intention-to-
treat (ITT) set comprising all patients with at least one
available post-baseline assessment of the primary ana-
lysis variable. The safety analysis included all patients
who had received at least one dose of trial medication.




Overall, 91 patients were enrolled (Fig. 1). One patient
withdrew consent immediately after randomization and
was not included in the ITT analysis (SUN/PL 45/45).
Demographic and baseline characteristics for the ITT
patient population compared with the evaluable popula-
tion for serum analysis are provided in Table 1.
Follow-up for progressive disease (PD) was carried out
at 3, 6, 9 and 12 months (±2 weeks) after the EOT visit
until progression. Progression was observed in 32 and
31 patients of the SUN and PL groups, respectively. In
6/9 of SUN/PL patients, respectively, progression was
observed >12 months after the EOT visit. At the end of
the study, 7/5 of SUN/PL patients were reported to have
no signs of PD.
Treatment
Patients in both groups started 2.7 cycles of treatment.
In total, 29 and 24 patients from the SUN and PL groups
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respectively, terminated treatment due to disease pro-
gression. Further reasons for ending treatment (SUN/
PL) were treatment interruption (3/2 patients), toxicity
(1/3 patients) and withdrawal of informed consent (1/2
patients).
Efficacy
Efficacy analysis was carried out on the ITT population.
Figure 2 illustrates the survival distribution per treat-
ment group for PFS and OS by Kaplan-Meier curves.
The median PFS was similar in both groups, 107 and
99 days (3.5 vs. 3.3 months) for SUN and PL patients,
respectively (HR 1.11, 95 % CI 0.70–1.74, P = 0.66). The
OS showed a trend in favor of SUN compared with PL,
315 vs. 270 days (10.4 vs. 8.9 months). However, the dif-
ference was not statistically significant (HR 0.82, 95 %
CI 0.50–1.34, P = 0.42). The probability of 1-year sur-
vival was 34 % and 36 %, and the probability of living
180 days was 0.65 and 0.57 for the SUN and PL groups,
respectively.
Evaluation of response and tumor control was per-
formed in the ITT population (Table 1). Best responses
according to RECIST 1.1 were defined in 79 patients
(Table 1). Objective response and tumor control were
achieved in 20 %/29 % and 58 %/56 % for FOLFIRI +
SUN/FOLFIRI + PL, respectively. Disease progression
was the cause of death in 32 % of patients treated with
SUN and in 31 % of PL patients.
Fig. 1 Consort flow diagram
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Table 1 Demographic, baseline and response characteristics in the ITT population and serum analysis subpopulation
Characteristic ITT population Serum analysis population
Sunitinib Placebo Sunitinib Placebo
N n (%) N n (%) N n (%) N n (%)
Number of patients 45 100 45 100 34 100 31 100
Age (years)
Mean (SD) 59 (11) 57 (11) 57 (12) 58 (12)
Median (Range) 62 57 60 60
(37–76) (28–84) (37–76) (28–84)
Gender
Male 33 73 30 67 25 74 18 58
Female 12 27 15 33 9 26 13 42
Karnofsky performance status
90–100 % 27 60 26 58 22 65 19 61
70–80 % 16 36 18 40 10 29 11 25
Not known 2 4 1 2 2 6 1 3
Histology: Adenocarcinoma of
Stomach 22 49 23 51 17 50 17 55
Cardia 23 51 20 44 17 50 14 45
Not known 0 0 2 4 0 0 0 0
Treatment lines before study entry
1 34 76 34 76 26 76 24 77
2 9 20 11 24 6 18 7 23
3 1 2 – – 2 6 – –
Not known 1 2 0 0 0 0 0 0
Screening pT-stadium
0 – – 1 2 – – 1 3
1 1 2 1 2 1 3 1 3
2 5 11 7 16 4 12 6 19
3 21 47 18 40 17 50 9 29
4 7 16 9 20 6 18 7 23
X 11 24 9 20 6 18 7 23
Screening pN-stadium
0 2 4 7 16 1 3 6 19
1 16 36 11 24 16 47 7 23
+ – – 1 2 – – – –
2 9 20 8 18 7 21 7 23
3 8 18 6 13 7 21 5 16
X 10 22 12 27 3 9 6 19
Screening pM-stadium
0 9 20 4 9 8 24 3 10
1 36 80 41 91 26 77 28 90
Best response
Complete response (CR) – – 5 11 – – 4 13
Partial response (PR) 9 20 8 18 8 24 6 19
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Table 1 Demographic, baseline and response characteristics in the ITT population and serum analysis subpopulation (Continued)
Stable disease (SD) 18 40 12 27 17 50 9 29
Progressive disease (PD) 14 31 16 36 8 24 12 39
Not evaluable 4 9 4 9 1 3 – –
Objective response (CR + PR) 9 20 13 29 8 24 10 32
Tumor control rate (CR + PR + SD) 27 60 25 56 25 74 19 61
SD standard deviation
Fig. 2 Kaplan-Meier curves for progression-free survival and overall survival in the primary analysis population (ITT). Hazard ratios estimated by
Cox proportional hazards model. PFS, progression-free survival; HR, hazard ratio; ITT, intention-to-treat
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Safety and tolerability
Overall, 43 SUN and 42 PL patients experienced at least
one AE. In total, 33 SUN and 31 PL patients had at least
one AE CTC-Grade >3. CTC-Grade 4 and Grade 5 AEs
were reported in 15/7 and 3/5 of SUN/PL patients, re-
spectively. The frequencies of grade ≥3 AEs are shown
in Table 2.
AEs of Grade ≥3 at least possibly related to study
medication comprised neutropenia (24/8), leucopenia
(11/5), diarrhea (0/4), mucosal inflammation (2/2), fa-
tigue (0/3), pulmonary embolism (2/1), nausea (1/2), and
vomiting (2/1) for SUN/PL patients, respectively. With
the notable exception of neutropenia (P < 0.001), all pro-
portions of patients exhibiting an AE were statistically
not significant. No unexpected toxicities/AEs occurred
with SUN.
Biomarker analysis
No significant correlations of any biomarker levels to
age, gender, lymph node or distant metastases were
found. Similar PFS and OS results in the observed sub-
group and the ITT population, suggest an absence of
bias. Tables 3 and 4 summarize the main findings.
SDF-1α/CXCL12
Blood samples of 50 patients were available for bio-
marker analysis of SDF-1α. A significant increase of
SDF-1α from median baseline levels of 143 pg/ml to
337 pg/ml at day 1 of cycle 2 was detected for PL only
(Wilcoxon matched-pairs test P = 0.041). No significant
benefit for PFS or OS could be shown in the small sub-
group of this biomarker analysis. A trend for longer PFS
in both treatment arms with an increase in SDF-1α from
baseline to cycle 2 was shown (Wilcoxon matched-pairs
test P = 0.058).
VEGF-A
The median baseline serum level of VEGF-A was
58.7 pg/ml for 65 evaluable patients. There was a signifi-
cant reduction in VEGF-A levels from baseline to day 14
of the first cycle in the SUN group (Wilcoxon matched-
pairs test P = 0.017). Interestingly, we detected a signifi-
cant decrease of VEGF-A levels from baseline to day 1
of cycle 2 for the PL group only (P = 0.033). For the PL
group, a similar trend towards reduction of VEGF-A
levels from baseline to day 1 of cycle 3 could be shown
(P = 0.062). In contrast, no change between baseline and
day 1 of cycle 2 could be shown for patients receiving
SUN. Moreover, this result was supported by a trend to
an increase in VEGF-A concentration from day 14 of
cycle 1 to predose measurement on day 1 of cycle 2 for
the SUN group only (P = 0.10). A VEGF-A reduction
from baseline to day 14 of cycle 1 correlated positively
with longer OS in the PL group only (HR 0.286, 95 % CI
0.101–0.814, P = 0.019).
Independent of treatment, low VEGF-A baseline
values were significantly associated with longer PFS
(Fig. 3). Additionally, a strong trend to a longer OS of
11.07 months ± 63 days for the group with low VEGF-A
baseline levels versus 7.56 months ± 73 days (HR 0.602,
95 % CI 0.356–1.018, P = 0.058) was detected.
sVEGFR2
The median concentration of sVEGFR2 prior to the start
of study treatment was 4688 pg/ml for 65 evaluable pa-
tients. Analysis of serum values showed significantly de-
creased sVEGFR2 after 14 days drug intake during cycle
1 in the SUN group (Wilcoxon matched-pairs test P =
0.012). A change from a median level of 4613 pg/ml to
4197 pg/ml after 14 days was observed. Furthermore,
concentrations on day 1 of cycle 2 were significantly
lower than baseline in the SUN group (4238 pg/ml, Wil-
coxon matched-pairs test P = 0.006). Between baseline
and day 1 of cycle 3 a similar trend for a total of 18
available patient samples with a median concentration of
4312 pg/ml could be shown (P = 0.078). In contrast no
significant level changes could be determined for pa-
tients in the PL group. High sVEGFR2 baseline levels
Table 2 Frequency of adverse events grade≥ 3, reported in ≥ 2
(4 %) of patients of either group regardless of causality
Adverse events Sunitinib plus FOLFIRIa Placebo plus FOLFIRIa
N = 45 100 % N = 45 100 %
Neutropenia 25 56 9 20
Leucopenia 12 27 7 16
Diarrhea 1 2 6 13
Nausea 3 7 3 7
Vomiting 3 7 3 7
Fatigue - - 4 9
Pain - - 4 9
Pulmonary embolism 2 4 2 4
General physical health
deterioration
2 4 2 4
Mucosal inflammation 2 4 2 4
Gamma-glutamyltransferase
increased
3 7 1 2
Pneumonia - - 3 7
Subileus - - 3 7
Blood acid phosphatase
increased
2 4 - -
Blood bilirubin increased 2 4 - -
FOLFIRI 5-fluorouracil, leucovorin and irinotecan
aSchedule: 4/2, 4 weeks on treatment, followed by 2 weeks off; dosage:
starting dose 25 mg/day
Neutropenia: p < 0.001, leucopenia p = 0.20, all other items statistically not
significant (Fisher’s exact test)
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significantly correlated with a longer PFS (HR 1.682,
95 % CI 1.014–2.789, P = 0.044). Additionally, we found
a relationship between high sVEGFR2 levels on day 1 of
cycle 2 and longer PFS independent of treatment (HR
2.557, 95 % CI 1.248–5.237, P = 0.010) as shown in Fig. 4.
However for OS, no association of sVEGFR2 was found
in the analyses.
VEGF-D
Serum samples from 64 patients with a median baseline
concentration of 712.4 pg/ml were available for analysis
of VEGF-D. The comparison of VEGF-D levels between
baseline and day 14 of cycle 1 showed a significant in-
crease in the SUN group (Wilcoxon matched-pairs test
with median values of 681 pg/ml to 913 pg/ml, P <
0.001), but no change in the PL group. Furthermore, a
similar trend to higher VEGF-D levels on day 1 of cycle
2 was shown for patients receiving SUN (681 pg/ml to
807 pg/ml, P = 0.19).
The population was then stratified into two groups
depending on best response: 46 patients without object-
ive response (stable disease or progression) and 18 pa-
tients with a proven objective response (complete or
partial response). For patients with an objective re-
sponse, high VEGF-D baseline concentrations were as-
sociated with a longer PFS independent of treatment
(11.1 vs. 4.1 months, HR 0.189, 95 % CI 0.056–0.637, P
= 0.007; Fig. 5). An analysis following patient separation
into quartile groups according to their VEGF-D base-
line concentration confirmed that the longest median
PFS for patients were associated with the highest base-
line values above the 75 percentile (HR 1.801, 95 % CI
1.033–3.141, P = 0.038). Moreover, high VEGF-D levels
on day 1 of cycle 2 also correlated with significantly
longer PFS in the group with objective response (HR
4.236, 95 % CI 1.226–14.638, P = 0.023). Similar to
sVEGFR2 however, no association of VEGF-D with OS
was found, in the analyses.




Δδ day 14 of cycle 1 - baseline P value Δδ day 1 of cycle 2 - baseline P value Δδ day 1 of cycle 3 - baseline P value
VEGF-A Sunitinib -0.6816 (1.43) 0.017 -0.1393 (1.83) 0.831 0.1111 (1.26) 0.975
Placebo -0.3134 (1.24) 0.472 -0.7184 (1.32) 0.033 -1.1177 (1.92) 0.062
sVEGFR2 Sunitinib -0.0648 (0.17) 0.012 -0.0854 (0.12) 0.006 -0.0727 (0.14) 0.078
Placebo -0.0086 (0.12) 0. 222 -0.0216 (0.10) 0.472 0.0306 (0.20) 0.910
VEGF-D Sunitinib 0.2476 (0.26) <0.001 0.1038 (0.27) 0.131 0.0914 (0.20) 0.133
Placebo -0.1093 (0.66) 0.616 -0.0094 (0.19) 0.811 -0.1061 (0.25) 0.281
SDF-1α Sunitinib 0.0914 (0.47) 0.756 0.2912 (0.92) 0.730 - -
Placebo -0.0827 (0.93) 0.820 0.3572 (0.85) 0.041 - -
aData are presented as mean (SD). P < 0.05 marked in boldface and considered significant using paired Wilcoxon test
Table 4 Association between biomarker serum levels and outcome
Serum biomarker PFS OS
Median
(days)
HR (95 % CI) Median
(days)
HR (95 % CI)
P value P value
VEGF-A low-level baseline 166 0.533 329 0.602
high-level baseline 91 (0.318–0.895) 270 (0.356–1.018)
P = 0.017 P = 0.058
sVEGFR2 low-level baseline 107 1.682 293 1.148
high-level baseline 167 (1.014–2.789) 330 (0.648–1.927)
P = 0.044 P = 0.601
VEGF-D low-level baseline 123 1.670 310 0.888
high-level baseline 159 (0.760 –3.673) 300 (0.527–1.496)
P = 0.200 P = 0.654
SDF-1α low-level baseline 160 0.749 300 0.783
high-level baseline 129 (0.417–1.321) 329 (0.429–1.431)
P = 0.310 P = 0.427
HR hazard ratio, PFS progression free survival, OS overall survival, CI confidence interval. P < 0.05 marked in boldface
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Discussion
Patients with chemorefractory AGC have a poor progno-
sis. After failure of first-line treatment, various options
for second-line treatment have been analyzed in previ-
ous studies, but median OS has always remained below
10 months. Recent randomized phase III trials of
second-line chemotherapy versus BSC have reported
even lower OS times [6, 7, 31]. Here, FOLFIRI has been
considered to be an established option after failure of a
platinum-containing first-line therapy [2]. Other TKIs
such as erlotinib and gefitinib have been under investiga-
tion in the first- and second-line treatment of gastric
cancer [17, 32, 33]. Ramucirumab, a fully humanized
monoclonal antibody targeting VEGFR2, recently showed
a significant OS benefit as second-line monotherapy and
in combination with paclitaxel [34, 35].
In our study, a beneficial effect of SUN added to FOL-
FIRI on the endpoints PFS, OS and duration of disease
stabilization could not be verified. The primary end-
point, PFS, was similar for FOLFIRI + SUN versus FOL-
FIRI + PL. Regarding OS however, patients receiving
SUN had a trend towards a better OS with a median OS
of 315 versus 270 days compared with PL. In terms of
OS, the benefit of second-line therapy versus BSC has
already been demonstrated in trials such as those of
Thuss-Patience et al. and Kang et al. [6, 7]. Two previ-
ous second-line, phase II studies with SUN alone re-
ported medians for PFS of 1.3 and 2.3 months and for
OS of 5.8 and 6.8 months, respectively [28, 29]. Even if
cross study comparison has limitations, FOLFIRI com-
bined with SUN showed an additional improvement with
respect to those endpoints compared to SUN or FOL-
FIRI alone.
Generally, the combination of SUN and FOLFIRI was
well tolerated. No unexpected toxicities occurred in pa-
tients receiving SUN, demonstrating the safety of such a
second-line combination. These data are consistent with a
phase I dose-escalation study of the FOLFIRI + SUN regi-
men [36] and a study of SUN alone in patients with che-
morefractory AGC. With respect to non-hematological
AEs, diarrhea, vomiting, and lethargy were also most fre-
quent in patients being treated with the higher dose of
37.5 mg/day SUN [36]. The higher frequency of non-
hematological toxicities observed in the current study may
be attributed to the backbone chemotherapy or underlying
disease, characterized by the weaker general condition of
second-line AGC patients [28]. Similar studies investigat-
ing FOLFIRI in patients with AGC have reported neutro-
penia, anemia, nausea, diarrhea, and stomatitis as
common toxicities as observed in our study [37, 38]. The
Fig. 3 Kaplan-Meier curves for progression-free survival depending on VEGF-A at baseline dichotomized at the median 58.7 pg/l. Hazard ratio
0.533, 95 % CI 0.318–0.895, P = 0.017
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FOLFIRI combination with daily 37.5 mg SUN versus PL
has also been investigated in patients with metastatic colo-
rectal cancer (mCRC) [39]. This phase III study was
stopped prematurely due to the occurrence of more grade
≥3 AEs with SUN than PL and a high incidence of
toxicity-related deaths. However, these differences between
the treatment arms were less marked in our study com-
pared with those observed in patients with mCRC. Since
toxicity-related deaths were also less frequent, the lower
daily dose of 25 mg SUN may be a more attractive dose
level for combination with FOLFIRI. As indicated by Park
et al. [40] quality of life (QoL) should be a consideration
when considering second-line therapies. Based on the
EORTC QLQ-C30 and HADS questionnaires, QoL in our
trial was nearly always in favor of SUN (data not shown).
Serum was used for biomarker analysis in our study.
No adjustment of the platelet factor was performed for
the biomarker concentrations. Both serum and plasma
VEGF levels have been reported as prognostic biomarker
for survival in gastric cancer and other tumors [12, 41].
Nevertheless, the appropriate specimen to analyze have
been discussed extensively in previous literature. For in-
stance Lee et al. suggested serum analysis for VEGF level
determination even being affected by platelet-derived
VEGF [42, 43].
With regard to the tested biomarkers in our analysis,
SUN induced a significant decrease in sVEGFR2 con-
centration during the first 6 weeks of treatment. Inter-
estingly, higher sVEGFR2 levels during the first 6 weeks
of study treatment indicated a longer PFS independent
of treatment group. With respect to VEGF-A serum
levels, firstly a decrease was observed after 14 days
treatment combined with a VEGF-A increase after
treatment rest in the SUN group. Additionally, an in-
crease in VEGF-D levels in SUN-treated patients during
the first 6 weeks of therapy was observed. High VEGF-
A baseline levels were prognostic for shorter PFS in
both study groups. Additionally, a trend towards
shorter OS was shown for patients with a high VEGF-A
baseline. A significant improvement in PFS or OS with
respect to VEGF-D levels was noted for patients with
objective response during treatment only. These find-
ings confirm previous investigations suggesting VEGF-
A, −D and sVEGFR2 as potential prognostic biomarkers
for therapy-resistant patient outcome [12, 44]. Here,
our results highlight again the complexity of the patho-
mechanisms and the difficulties in the treatment of GC,
as no identified biomarker level change during SUN
treatment directly correlated with response or survival
benefit [45, 46].
Fig. 4 Kaplan-Meier curves for progression-free survival depending on sVEGFR2 at baseline dichotomized at the median 4688 pg/ml. Hazard ratio
2.557, 95 % CI 1.248–5.237, P = 0.010
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Fig. 5 Kaplan-Meier curves for progression-free survival depending on VEGF-D baseline and objective response dichotomized at the median >712 pg/l.
Patients without objective response: Hazard ratio for VEGF-D: 1.192, 95 % CI 0.657–2.164, P = 0.56, N = 46. Patients with objective response: Hazard ratio
for VEGF-D: 0.189, 95 % CI 0.056–0.637, P = 0.007, N = 18
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Conclusion
In summary, although FOLFIRI + SUN demonstrated
positive trends in overall survival times, the study did
not meet its primary endpoint. The median PFS was
similar in both groups. Nevertheless, to our knowledge,
no biomarker results under these treatment regimens
have been published to show the effects on in-vivo
angiogenesis. Thus, novel therapy concepts targeting
sVEGFR2 and other VEGF group members to normalize
vascularization in therapy-resistant tumor tissue should be
developed together with biomarkers, such as serum or
protein expression levels during anticancer treatment [47].
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